Skip to content
AnalystLens

Halozyme Therapeutics Quarterly Report for Q1 Ended Mar 31, 2024

Filing Date
Filed May 7, 2024
Period End
March 31, 2024
Security
HALO
One revenue dollarkept$0.39
In the record · 2016–202610-K1110-Q328-K140

HALO filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 140 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Material agreement8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 10-Q filed May 7, 2024. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. reported first-quarter 2024 total revenues of $195.9 milliona, up from $162.1 million in the prior-year quarter, and net income of $76.8 million, or $0.60 per diluted share, compared with $39.6 million, or $0.29 per diluted share, a year earlier.

Royalties rose to $120.6 millionb from $99.6 million, driven primarily by continued uptake of DARZALEX SC by Janssen and Phesgo by Roche and the launch of Vyvgart by argenx. Revenues under collaborative agreements increased to $16.7 million, including $14.0 million in event-based development and regulatory milestones. Product sales, net declined to $58.6 million from $60.8 million, mainly due to lower bulk rHuPH20 sales from the timing of shipments to partners, partially offset by growth in proprietary product sales of $35.3 million.

The balance sheet strengthened, with cash, cash equivalents and marketable securities totaling $463.5 millionc at March 31, 2024, and stockholders' equity rising to $177.8 million from $83.8 million at December 31, 2023. Operating cash flow was $129.4 million, compared with $86.96 million a year earlier. Long-term debt, net was $1.50 billion, consisting of the 2027 and 2028 Convertible Notes, and the $575 million revolving credit facility was undrawn.

The company repurchased no shares in the quarter, and in February 2024 its board authorized a new $750.0 milliond capital return program. Management stated that the company believes its cash, cash equivalents and marketable securities will be sufficient to fund operations for at least the next twelve months. The filing notes expected fluctuations in collaborative and bulk rHuPH20 revenues tied to partner milestones and shipment timing, and recent partner regulatory milestones, including a $15.0 million milestone tied to the FDA's acceptance of BMS's Opdivo SC BLA.

Key Highlights

  1. Total revenues of $195.9 million, up from $162.1 million, with royalties of $120.6 million (up 21%).
  2. Net income of $76.8 million ($0.60 diluted EPS) versus $39.6 million ($0.29 diluted EPS) in Q1 2023.
  3. Operating income of $95.5 million, up from $53.8 million, and operating cash flow of $129.4 million.
  4. Collaborative revenue of $16.7 million, including $14.0 million in event-based development and regulatory milestones.
  5. Product sales, net declined 4% to $58.6 million, as bulk rHuPH20 sales fell 52% on shipment timing; proprietary product sales rose 26% to $35.3 million.
  6. Cash, cash equivalents and marketable securities of $463.5 million; the $575 million revolver was undrawn at quarter end.
  7. Board authorized a new $750.0 million share repurchase program in February 2024; no shares were repurchased in Q1 2024.

Follow one dollar

Of each $1.00 of revenue in Q1 FY2024, Halozyme Therapeutics kept $0.39.

  1. Revenue$195.9M100.0%
  2. Cost of revenue−$28.3M14.5%
  3. Gross profit$167.6M85.5%
  4. Operating costs−$72.0M36.8%
  5. Operating income$95.5M48.8%
  6. Interest, other & tax−$18.7M9.6%
  7. Net income$76.8M39.2%
Computed from 10-QQ1 FY2024filed May 7, 2024Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q1 FY2024 against Q1 FY2023

Line itemQ1 FY2024Q1 FY2023Change
Revenue$195.88M$162.14M+20.8%
Cost of Revenue$28.33M$35.17M−19.5%
Gross Profit$167.55M$126.97M+32.0%
R&D Expenses$19.11M$17.98M+6.3%
SG&A Expenses$35.13M$37.36M−6.0%
Operating Expenses$100.34M$108.34M−7.4%
Operating Income$95.54M$53.80M+77.6%
Interest Expense$4.51M$4.54M−0.8%
Net Income$76.82M$39.62M+93.9%
EPS (Basic)$0.61$0.29+110.3%
EPS (Diluted)$0.60$0.29+106.9%
Shares Outstanding (Basic)126.94M135.03M−6.0%
Shares Outstanding (Diluted)128.89M137.90M−6.5%

Frequently Asked Questions

  1. What drove the growth in royalty revenue?

    The filing attributes the 21% increase in royalties to continued sales uptake of DARZALEX SC by Janssen and Phesgo by Roche in all geographies and the launch of Vyvgart by argenx, partially offset by slightly lower sales of Herceptin SC and MabThera SC by Roche.

  2. Why did product sales decline year over year?

    Product sales, net fell 4% to $58.6 million, primarily due to lower bulk rHuPH20 sales from the timing of shipments to partners, partially offset by contributions from proprietary and device partnered products.

  3. Is the company's liquidity sufficient?

    Management believes existing cash, cash equivalents and marketable securities of $463.5 million will be sufficient to fund operations for at least the next twelve months, and the $575 million revolving credit facility was undrawn as of March 31, 2024.

  4. What is the company's debt position?

    Long-term debt, net was $1.50 billion at March 31, 2024, consisting of 0.25% Convertible Notes due 2027 ($805.0 million principal) and 1.00% Convertible Notes due 2028 ($720.0 million principal). The company stated it was in compliance with all covenants, and the 2028 notes were not convertible as of quarter end.

  5. What capital return activity occurred?

    No common stock was repurchased in Q1 2024, compared with $150.1 million in the prior-year quarter. In February 2024, the Board authorized a new capital return program to repurchase up to $750.0 million of outstanding common stock.